- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05092646
Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis (Phoenix)
A Double-blind, Multi-Center, Prospective, Randomized Placebo-controlled Pilot Study Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Aaron J. Tabor, PhD, CTBS
- Phone Number: 6027259505
- Email: atabor@axobio.com
Study Contact Backup
- Name: Jennifer Jennings
- Phone Number: 202.742.3861
- Email: jjennings@mcra.com
Study Locations
-
-
Idaho
-
Boise, Idaho, United States, 83713
- Injury Care Research
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Orthopedic Specialists of Louisiana
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- OrthoCarolina Foot and Ankle Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed written informed consent
- Willing to be randomized to either the investigational or control group
- Male or female at least 18 years of age and less than 80
- Clinical diagnosis of symptomatic tibiotalar (ankle) OA (primary idiopathic OA or post-traumatic OA), modified K-L grade 1-3a
- One ankle is the most symptomatic lower extremity joint and the only lower extremity joint currently planned for treatment
- Willing and able to comply with all study requirements including all postoperative clinical and radiographic evaluations
- For women of childbearing potential (not post-menopausal for 12 months or surgically sterile), a urine pregnancy test with a negative result must be obtained at screening and on the day of procedure, prior to injection
- Male and female trial participants must commit to adequate birth control (e.g., surgically sterilized, oral contraceptive, two methods of barrier birth control, or abstinence) through the final follow-up
- Chronic ankle pain for ≥ 6 months
- SAOS Pain score ≥ 30 and ≤ 80 and AOS Function score ≥ 30 and ≤ 80
- Willing to discontinue all prescription and over-the-counter pain medications being used for ankle OA symptoms for the duration of the study, except for acetaminophen, which is not allowed for the 3 days preceding each scheduled follow-up visit and the day of the follow-up visit.
Exclusion Criteria:
- Previously received intra-articular injections in the index joint of Axolotl Ambient, bone marrow aspirate concentrate (BMAC), platelet-rich plasma (PRP), or other biologic-based products within the last 12 months.
- Modified K-L Grade 3b or 4 osteoarthritis of the index joint
- Diagnosis of ipsilateral peri-articular arthritis (e.g. subtalar joint) that the investigator determines may significantly confound the study results
- Received intra-articular hyaluronic acid injection in the index joint within the last 6 months
- Received intra-articular steroid injection in the index joint within the last 3 months
- Prior major surgical repair or reconstruction of the ankle that the investigator determines may significantly confound the study results
- Baseline pain catastrophizing score ≥ 23
- Any surgery of the index ankle within the last 12 months
- Planned arthroscopy or other procedure on the ankle during the study
- Bilateral ankle OA requiring treatment of both ankles
- Pregnancy, breastfeeding, or woman of child-bearing potential not using adequate contraception
- Bone deficit
- Charcot foot disease
- Radiographic evidence of open epiphyses
- Systemic inflammatory condition
- Substantial vascular insufficiency
- Current treatment with anticoagulants
- Deformity in coronal, axial or sagittal plane greater the 30°
- Patients weighing less than 47 kg.
- BMI greater than 45 kg/m2
- Documented medical history of, or radiographic evidence of, a bone disease (e.g. severe osteoporosis or avascular necrosis) or other condition (e.g., osteolysis)
- Comorbidity that would limit the ability to administer any functional measurements
- Has at the time of injection, a systemic or local infection at the site of injection
- Medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival or interfere with ambulation or rehabilitation (e.g., history of transient ischemic attack, stroke or liver disease)
- Known hypersensitivity to penicillin
- Known allergy to phenol red
- Currently receiving treatment with a drug known to interfere with bone or cartilage metabolism [e.g., systemic steroid therapy (topical steroid therapy is permissible), methotrexate]
- Medical condition requiring radiation, chemotherapy or immunosuppression
- Have an active history of malignancy (except for basal cell carcinoma of the skin)
- Has a history of autoimmune disease known to affect bone or cartilage. Examples include spondyloarthropathies (e.g., ankylosing spondylitis, Crohn's disease, and ulcerative colitis), Juvenile Arthritis, rheumatoid arthritis, Grave's disease, and Hashimoto's thyroiditis
- Has obvious or documented alcohol or illicit drug addictions
- Is a prisoner in a correctional institution/facility
- Actively involved in litigation or workman's compensation
- Has participated in clinical studies evaluating investigational devices, pharmaceuticals or biologics within 6 months of randomization
- Bedridden, confined to a wheelchair, or unable to walk 50 m without the help of a walker, crutches, or cane
- Is currently taking prescription pain medication for any conditions other than ankle osteoarthritis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control Group
Single dose, 2.0 mL of 0.9% normal saline, administered via intra-articular injection administered to the affected tibiotalar joint.
|
"Drug/Placebo: 0.9% Normal Saline"
|
Experimental: Investigational Group
Biological/Vaccine: Axolotl Ambient Axolotl Ambient is an allogeneic amniotic intraarticular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells. Other Names: • CA20 |
Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients achieving Composite Clinical Success
Time Frame: 4 Weeks
|
Changes from baseline to each follow-up timepoint (4 weeks, 3 and 6 months) will be calculated for each outcome metric and statistical significance of changes will be assessed through repeated measures ANOVA or a mixed effects model to accommodate missing data points. Two options (based on either AOS or FAOS scores) for CCS will be defined as:
AND
AND
|
4 Weeks
|
Proportion of patients achieving Composite Clinical Success
Time Frame: 3 Months
|
Changes from baseline to each follow-up timepoint (4 weeks, 3 and 6 months) will be calculated for each outcome metric and statistical significance of changes will be assessed through repeated measures ANOVA or a mixed effects model to accommodate missing data points. Two options (based on either AOS or FAOS scores) for CCS will be defined as:
AND
AND
|
3 Months
|
Proportion of patients achieving Composite Clinical Success
Time Frame: 6 Months
|
Changes from baseline to each follow-up timepoint (4 weeks, 3 and 6 months) will be calculated for each outcome metric and statistical significance of changes will be assessed through repeated measures ANOVA or a mixed effects model to accommodate missing data points. Two options (based on either AOS or FAOS scores) for CCS will be defined as:
AND
AND
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events
Time Frame: Baseline (Day 0) to 12 Months
|
An Adverse Event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in study subjects whether or not considered related to the investigational product.
This definition includes events related to the investigational product or the comparator and events related to the procedures involved.
|
Baseline (Day 0) to 12 Months
|
Symptoms, Quality of Life and Sports and Recreation subscales of the FAOS
Time Frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
The FAOS score was developed to reflect a foot and ankle version of the Knee Osteoarthritis Outcomes Score (KOOS).
The FAOS score includes symptoms, quality of life and sports and recreation subscales.
|
Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
Visual Analog Scale for average ankle pain and worst ankle pain
Time Frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
The Visual Analog Scale (VAS) is a measure of pain intensity.
It is a continuous scale comprised of a horizontal visual analog scale anchored by two verbal descriptors (one for each symptom extreme).
|
Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
EuroQOL-5 dimension-5 level quality of life scale
Time Frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
EQ-5D-5L is a self-completed health status questionnaire that assesses quality of life.
|
Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
Pain Catastrophizing Scale
Time Frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
The pain catastrophizing scale (PCS) is a 13-item questionnaire that asks participants to grade each item on a 5-point scale.
|
Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
Current Working Status
Time Frame: Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
Percent of subject responses, for each of the following work status categories, by the treatment and control groups, at each timepoint. Current Working status, at each timepoint will be collected as: Not working, unrelated to ankle Not working, related to ankle Working with major limitations related to ankle Working without limitations related to ankle |
Baseline (Day 0), 4 Weeks, 3 Months, 6 Months, and 12 Months
|
Modified Kellgren and Lawrence Grade
Time Frame: Baseline (Day 0), 6 Months
|
The modified Kellgren and Lawrence Grade (K-L Grade) classifies osteoarthritis using five grades based on evaluation of x-ray of the affected joint.
|
Baseline (Day 0), 6 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Robert S. Kellar, PhD, Chief Science Officer (CSO)
- Study Director: Aaron J. Tabor, PhD, CTBS, V.P. of Clinical Operations
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA-2021-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ankle Osteoarthritis
-
University of IowaUniversity of Delaware; Bio-Mechanical Composites; Fabtech SystemsCompletedPost-traumatic Osteoarthritis | Ankle Fractures | Osteoarthritis AnkleUnited States
-
University of IowaWithdrawnPost-traumatic Osteoarthritis | Ankle Fractures | Osteoarthritis AnkleUnited States
-
DT MedTech, LLCRecruitingOsteoarthritis Ankle | Post-Traumatic Osteoarthritis of Ankle | Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)United States
-
University of Missouri-ColumbiaCompletedAnkle Injuries | Ankle Osteoarthritis | Post-Traumatic Osteoarthritis of AnkleUnited States
-
Duke UniversityMedartis AGCompletedPost-traumatic Osteoarthritis, Unspecified Ankle and Foot | Localized, Primary Osteoarthritis of the Ankle and/or FootUnited States
-
Orthopaedic Associates of Michigan, PCCompletedRheumatoid Arthritis of Ankle | Osteoarthritis of Ankle | Traumatic Arthritis of AnkleUnited States
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
National Scientific Center of Traumatology and...RecruitingAnkle OsteoarthritisKazakhstan
-
Istituto Ortopedico RizzoliActive, not recruiting
-
VA Office of Research and DevelopmentActive, not recruitingAnkle OsteoarthritisUnited States
Clinical Trials on "Drug/Placebo: 0.9% Normal Saline"
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
University of Texas Southwestern Medical CenterCompletedAcute BronchiolitisUnited States
-
GemVax & KaelCompletedBenign Prostatic Hyperplasia (BPH)Korea, Republic of
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
Mayo ClinicWithdrawnHeart Failure | Left Ventricular Assist Device | Natriuretic Peptide
-
BioAegis Therapeutics Inc.CompletedCommunity-acquired PneumoniaAustralia, Georgia
-
University of HaifaWestern Galilee Hospital-NahariyaRecruiting
-
Virginia Commonwealth UniversityUnited States Department of DefenseWithdrawn
-
PhytoHealth CorporationRecruitingCancer-related FatigueTaiwan
-
Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Center for Research...Active, not recruitingOrthostatic Intolerance | Postural Tachycardia Syndrome | Orthostatic TachycardiaUnited States